Drug Trial Radar · NCT06049212
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 26, 2023
Primary completion
Dec 31, 2027
Study completion Jan 29, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC). Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed.
Conditions
- Non-small Cell Lung Cancer
- Solid Tumors
- Programmed Cell Death-1 (PD1, PD-1)
- Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
- Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Interventions
Sacituzumab tirumotecanBiological
Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.
PembrolizumabBiological
Pembrolizumab solution for IV infusion.
Supportive care measuresDrug
Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days after each dose
- Number of Participants Experiencing ≥1 Adverse Event (AE)Time frame: Up to ~32 months
- Number of Participants Discontinuing from Study Therapy due to AETime frame: Up to ~32 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Aichi Cancer Center ( Site 0006)
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 0002)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 0008)
Matsuyama, Ehime, Japan
Kanagawa Cancer Center ( Site 0004)
Yokohama, Kanagawa, Japan
Kansai Medical University Hospital ( Site 0007)
Hirakata, Osaka, Japan
Shizuoka Cancer Center ( Site 0005)
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital ( Site 0001)
Chuo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.